Listen to The Lancet Respiratory Medicine

Kerri Johannson from the University of Calgary discusses why recent treatment guidelines on the use of antacid therapy in patients with IPF have caused controversy.

Dr. Ganesh Raghu discusses the highly anticipated results of the WRAP-IPF trial, borne out of debate surrounding the role of GER in the pathogenesis and progression of IPF, and conflicting findings from retrospective studies of antacid therapies on survival and disease progression.

Dr Keith Chappell discusses the bivalent recombinant vaccine for COVID-19 following the study by Dayan and colleagues, with focus on vaccine access, variants and boosters, tolerability and side effects, as well as hopes for future trials.

Prof. James Chalmers discusses the characteristics of patients with bronchiectasis across Europe, the differences between countries, and possible differences in clinical outcomes, based on data from the EMBARC registry.

Dr Sandeep Sahay and Professor Franck Rahaghi discuss their Personal View on future treatment paradigms in pulmonary arterial hypertension.

Dr Margaux Mesle discusses estimates of lives directly saved by COVID-19 vaccination programs in the WHO European Region in the period from 2020 to 2023 and public health implications.

Professor Eric Lim discusses the outcomes after extended pleurectomy decortication plus chemotherapy versus chemotherapy alone for pleural mesothelioma.

Anne-Marie Dingemans, Isabelle Opiz, and Corinne Faivre-Finn talk about their multidisciplinary efforts to develop a consensus definition of stage III Non-Small Cell Lung Cancer technical resectability.

Anne Holland and Christine McDonald join Diana Stanley to discuss ambulatory oxygen for treatment of exertional hypoxaemia in pulmonary fibrosis.

Marion Moseby-Knappe talks about a prospective, international, observational biomarker study, within the Targeted Hypothermia versus Normothermia after Out-of-Hospital Cardiac Arrest (TTM2) trial, to compare four markers of brain injury for the prediction of functional outcome in patients after cardiac arrest using assays that can be analysed on clinically available equipment.

Series on Prematurity-associated lung disease and a conference session at 4pm GMT on 27/11/25

Dr Neil Greening and Dr Hnin Aung join Diana Stanley to discuss a new multidimensional prognostic risk stratification model for COPD exacerbations.

Dr Finn McQuaid and Dr Matthew Saunders join Arianna Colosio to discuss an analytical framework to describe potential causal relationships between climate change and tuberculosis.

Toby Maher joins us to discuss results of a randomised, double-blind, placebo-controlled, proof-of-concept trial of ENV-101, an oral inhibitor of the hedgehog signalling pathway, in patients with idiopathic pulmonary fibrosis.

Professors Guy Brusselle and Celeste Porsbjerg join us to discuss their recent Series papers on asthma, which will be featured in a cross journal project with The Lancet.

Diana Stanley, Deputy Editor at The Lancet Respiratory Medicine, is joined by Dr Joan Soriano to discuss a new series on the global epidemiology of respiratory disease, exploring the diagnostic challenges, global trends, and future directions for prevention.

Carole Mitnick & Lorenzo Guglielmetti join Ari Colosio, deputy editor of The Lancet Respiratory Medicine, to discuss the ENDTB-Q trial to evaluate the efficacy and safety of a drug regiment to treat TB in individuals with pre-extensively drug-resistant tuberculosis.

Lorenzo Guglielmetti sul trial clinico ENDTB-Q per valutare l’efficacia e la sicurezza di un regime di farmaci per curare la tubercolosi in individui con tubercolosi pre-estesa farmaco-resistente.

Ari Colosio speaks with Dr. Laura Garriga-Grimau about the first multi-country cohort study to describe the clinical features and standards of care for children and young people with bronchiectasis.

Bianca Brandon is joined by Professor Marcus Schultz and Dr Prashant Nasa to discuss their recent Position Paper reporting insights from an international Delphi expert panel on defining and subphenotyping ARDS.

Bianca Brandon, Senior Editor at The Lancet Respiratory Medicine, is joined by Professor Hjalmar Bouma to discuss a new review on sepsis in immunocompromised patients, exploring the diagnostic challenges, complexities of immune status, and future directions for targeted therapies.

Deputy Editor of The Lancet Respiratory Medicine Ari Colosio discusses the critical findings of a new epidemiological study on pulmonary embolism in children and adolescents with Simon Wolf from the University Hospital of Zurich.

Professor Sergio Harari joins us to discuss the results of a phase 2 clinical trial evaluating activity and safety of nintedanib in people with lymphangioleiomyomatosis (LAM).

Il Professor Sergio Harari commenta i risultati di un trial clinico di fase 2 volto a valutare l’attivita’ e la sicurezza del farmaco nintedanib come trattamento in pazienti affetti da linfangioleiomiomatosi (LAM).

Dr Robert Kullberg joins us to discuss his Viewpoint on empiric antibiotic therapy for sepsis and the importance of reducing unnecessary use of anti-anaerobic antibiotics.

Professor Heather Zar joins The Lancet Respiratory Medicine to discuss early-life RSV disease and long-term respiratory health. This topic will be covered in one of four Series papers in a cross-journal Series with The Lancet.

Professor James Hull joins us to discuss his recent Spotlight on protecting the respiratory health of athletes ahead of the Summer Olympics and Paralympics.

Dr Anne Chang discusses the burden of chronic respiratory diseases in Indigenous people.

Professor Daniel Steinfort and Professor Shankar Siva discuss the effect of systematic endoscopic mediastinal staging on radiotherapy field planning in patients with locally advanced non-small-cell lung cancer.

Prof Daniel Prieto-Alhambra, Dr Annika Jödicke, and Dr Martí Català discuss the effectiveness of COVID-19 vaccines to prevent Long COVID, estimated to affect up to 20% of those infected with SARS-CoV-2.

Dr Tim Nicholson and Dr Sarah Gorst discuss the development of an international Delphi consensus study on a core outcome measurement set for long COVID and how it will be used to inform future research and clinical care.

Dr Betty Raman discusses multiorgan MRI findings in patients after hospitalisation with COVID-19.

Prof Richard Costello discusses the use of digital measurements of medication adherence and lung function to guide management of uncontrolled asthma.

Dr Keiju Aokage discusses segmentectomy for ground-glass-dominant lung cancer with a tumour diameter of 3 cm or less.

Carol Hodgson discusses recent advances in our understanding of in-hospital and post-discharge outcomes in critically ill patients who receive ECMO.

Emma Grainger, Editor-in-Chief of The Lancet Respiratory Medicine, discusses the January issue and plans to celebrate the 10-year anniversary of the journal.

Vivienne Kahlmann and Catharina Moor discuss a study looking at online mindfulness-based cognitive behaviour treatment to address fatigue associated with sarcoidosis.

Yves Lacasse joins The Lancet Respiratory Medicine to discuss a meta-analysis on the effectiveness of home oxygen use for patients with COPD.

Rachael Evans discusses the needs of people with long COVID and the latest findings from the PHOSP-COVID study.

Daniel Munblit and Dale Needham discuss the importance of developing a core outcome set for post-COVID-19 condition.

Daiana Stolz discusses antibiotic stewardship in patients hospitalised with pneumonia and at risk of Gram-negative bacterial infection.

Dr Ablo Wachinou discusses the prevalence of sleep disordered breathing in Benin and how awareness and treatment might be improved.

Professor Peter Openshaw and Dr Felicity Liew discuss the use of inhaled corticosteroids in the early treatment of COVID and the involvement of the respiratory mucosa in response to viral infection.

Dr Dinh Bui discusses the association between very-to-moderate preterm birth and lung function deficits and COPD at age 53.

Ruvim Izickson discusses the safety and immunogenicity of administering a high-dose quadrivalent influenza vaccine together with a third dose of the Moderna COVID-19 vaccine in adults aged 65 years and older.

Wisia Wedzicha discusses findings of a trial of a vaccine for the prevention of COPD exacerbations and provides her insights for future research.

Eileen Rubin, author of a paper on advancing precision medicine for acute respiratory distress syndrome discusses her delayed diagnosis and how clinician and researcher goals can differ from those of patients.

Daniel Altmann discusses the duration of immune protection from COVID vaccination and the crucial implications for the implementation of booster vaccination programmes.

Comment author Michael Kreuter discusses a series of papers published in the Lancet and the Lancet Respiratory Medicine on interstitial lung disease.

Bairbre McNicholas and Jie Li discuss an open label superiority meta-trial looking at the efficacy of awake prone positioning for patients with COVID-19 acute hypoxaemic respiratory failure.